Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04099966 · ClinicalTrials.gov registry record · Phase 2
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
A Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma, sponsored by Mitchell Cairo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04099966: Recruiting Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma, sponsored by Mitchell Cairo.
NCT04099966 is a Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Mitchell Cairo. The registered enrollment target is 20 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04099966, a Phase 2 study of Sickle Cell Disease and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Mitchell Cairo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Primary Outcome
patients will be monitored for any adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells
Conditions Studied
Interventions
- DRUG alpha beta depletion
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT04099966 shows while recruiting
NCT04099966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower).
The record links to 9 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which alpha beta depletion is the first listed.
NCT04099966 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04099966 about?
NCT04099966 is a clinical study titled "AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion". Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
What is the current status of trial NCT04099966?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-04-01. Estimated completion is 2027-12-31.
What conditions does trial NCT04099966 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Leukemia, Severe Aplastic Anemia.
What interventions are being tested in trial NCT04099966?
The interventions under investigation include: alpha beta depletion (DRUG).
Who is sponsoring clinical trial NCT04099966?
This trial is sponsored by Mitchell Cairo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04099966 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04099966's enrollment target sits among peer trials
20 172nd of 213 higher than 33 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI